112 related articles for article (PubMed ID: 1695859)
1. Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT.
Stoessl AJ; Dourish CT; Iversen SD
Brain Res; 1990 May; 517(1-2):111-6. PubMed ID: 1695859
[TBL] [Abstract][Full Text] [Related]
2. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse.
Stoessl AJ; Dourish CT; Young SC; Williams BJ; Iversen SD; Iversen LL
Neurosci Lett; 1987 Oct; 80(3):321-6. PubMed ID: 2446214
[TBL] [Abstract][Full Text] [Related]
3. The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation.
Stoessl AJ; Dourish CT; Iversen SD
Psychopharmacology (Berl); 1988; 95(4):502-6. PubMed ID: 2463651
[TBL] [Abstract][Full Text] [Related]
4. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats.
Stoessl AJ; Dourish CT; Iversen SD
Br J Pharmacol; 1988 Jun; 94(2):285-7. PubMed ID: 2456111
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of senktide-induced tail whips.
Nordquist RE; Ballard TM; Algeyer B; Pauly-Evers M; Ozmen L; Spooren W
Neuropharmacology; 2010 Jan; 58(1):259-67. PubMed ID: 19540857
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
Cellier E; Barbot L; Regoli D; Couture R
Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
[TBL] [Abstract][Full Text] [Related]
7. Effects of ageing on tachykinin function in the basal ganglia.
Stoessl AJ; Polanski E; Frydryszak H
Brain Res; 1993 Dec; 632(1-2):21-8. PubMed ID: 7511976
[TBL] [Abstract][Full Text] [Related]
8. Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats.
Fone KC; Johnson JV; Bennett GW; Marsden CA
Br J Pharmacol; 1989 Mar; 96(3):599-608. PubMed ID: 2470455
[TBL] [Abstract][Full Text] [Related]
9. Localization of Fos-like immunoreactivity induced by the NK3 tachykinin receptor agonist, senktide, in the guinea-pig brain.
Yip J; Chahl LA
Br J Pharmacol; 1997 Oct; 122(4):715-25. PubMed ID: 9375969
[TBL] [Abstract][Full Text] [Related]
10. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
11. Low responsiveness to agents evoking 5-HT2 receptor-mediated behaviors in Sardinian alcohol-preferring rats.
Ciccocioppo R; Panocka I; Stefanini E; Gessa GL; Massi M
Pharmacol Biochem Behav; 1995 May; 51(1):21-7. PubMed ID: 7542392
[TBL] [Abstract][Full Text] [Related]
12. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice.
Berendsen HH; Broekkamp CL
Br J Pharmacol; 1990 Nov; 101(3):667-73. PubMed ID: 2150180
[TBL] [Abstract][Full Text] [Related]
13. Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide.
Stoessl AJ; Hill DR
Brain Res; 1990 Nov; 534(1-2):1-7. PubMed ID: 1705846
[TBL] [Abstract][Full Text] [Related]
14. A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists.
Green AR; Hall JE; Rees AR
Br J Pharmacol; 1981 Jul; 73(3):703-19. PubMed ID: 6166345
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist.
Stoessl AJ; Brackstone M; Rajakumar N; Gibson CJ
Brain Res; 1995 Nov; 700(1-2):115-20. PubMed ID: 8624700
[TBL] [Abstract][Full Text] [Related]
16. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
17. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions.
Stoessl AJ; Szczutkowski E; Glenn B; Watson I
Brain Res; 1991 Nov; 565(2):254-62. PubMed ID: 1668812
[TBL] [Abstract][Full Text] [Related]
18. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
19. The tachykinin NH2-senktide, a selective neurokinin B receptor agonist, is a very potent inhibitor of salt appetite in the rat.
Massi M; Polidori C; Gentili L; Perfumi M; de Caro G; Maggi CA
Neurosci Lett; 1988 Oct; 92(3):341-6. PubMed ID: 2462199
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory role on gastric secretion of a central NK-3 tachykinin receptor agonist, senktide.
Improta G; Broccardo M
Peptides; 1991; 12(6):1433-4. PubMed ID: 1726124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
